Int. J. Mol. Sci. 2011, 12(11), 8013-8026; doi:10.3390/ijms12118013
Article

Resorcylidene Aminoguanidine (RAG) Improves Cardiac Mitochondrial Bioenergetics Impaired by Hyperglycaemia in a Model of Experimental Diabetes

* email, email and email
Received: 25 July 2011; in revised form: 2 November 2011 / Accepted: 3 November 2011 / Published: 16 November 2011
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Diabetes is associated with a mitochondrial dysfunction. Hyperglycaemia is also clearly recognized as the primary culprit in the pathogenesis of cardiac complications. In response to glycation and oxidative stress, cardiac mitochondria undergo cumulative alterations, often leading to heart deterioration. There is a continuous search for innovative treatment strategies for protecting the heart mitochondria from the destructive impact of diabetes. Aminoguanidine derivatives have been successfully used in animal model studies on the treatment of experimental diabetes, as well as the diabetes-driven dysfunctions of peripheral tissues and cells. Considerable attention has been paid particularly to β-resorcylidene aminoguanidine (RAG), often shown as the efficient anti-glycation and anti-oxidant agent in both animal studies and in vitro experiments. The aim of the present study was to test the hypothesis that RAG improves oxidative phosphorylation and electron transport capacity in mitochondria impaired by hyperglycaemia. Diabetes mellitus was induced in Wistar rats by a single intraperitoneal injection of streptozotocin (70 mg/kg body weight). Heart mitochondria were isolated from healthy rats and rats with streptozotocin-diabetes. Mitochondrial respiratory capacity was measured by high resolution respirometry with the OROBOROS Oxygraph-2k according to experimental protocol including respiratory substrates and inhibitors. The results revealed that RAG protects the heart against diabetes-associated injury by improving the mitochondrial bioenergetics, thus suggesting a possible novel pharmacological strategy for cardioprotection.
Keywords: RAG (β-resorcylidene aminoguanidine); mitochondrial respiratory; streptozotocin diabetes; oxygraph Oroboros
PDF Full-text Download PDF Full-Text [321 KB, uploaded 19 June 2014 04:06 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Labieniec-Watala, M.; Siewiera, K.; Jozwiak, Z. Resorcylidene Aminoguanidine (RAG) Improves Cardiac Mitochondrial Bioenergetics Impaired by Hyperglycaemia in a Model of Experimental Diabetes. Int. J. Mol. Sci. 2011, 12, 8013-8026.

AMA Style

Labieniec-Watala M, Siewiera K, Jozwiak Z. Resorcylidene Aminoguanidine (RAG) Improves Cardiac Mitochondrial Bioenergetics Impaired by Hyperglycaemia in a Model of Experimental Diabetes. International Journal of Molecular Sciences. 2011; 12(11):8013-8026.

Chicago/Turabian Style

Labieniec-Watala, Magdalena; Siewiera, Karolina; Jozwiak, Zofia. 2011. "Resorcylidene Aminoguanidine (RAG) Improves Cardiac Mitochondrial Bioenergetics Impaired by Hyperglycaemia in a Model of Experimental Diabetes." Int. J. Mol. Sci. 12, no. 11: 8013-8026.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert